Matches in SemOpenAlex for { <https://semopenalex.org/work/W2181570036> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2181570036 endingPage "178" @default.
- W2181570036 startingPage "175" @default.
- W2181570036 abstract "Gemcitabine is an active agent for treatment of advanced nonsmall cell lung cancer (NSCLC). Weekly treatment with singleagent gemcitabine has shown response rates of 20% to 26%. This Phase II trial was conducted to determine the efficacy and safety of 1000 mg/m 2 gemcitabine administered weekly for 3 weeks followed by 1 week or rest (28-day cycle). Patients were required to have histologic evidence of NSCLC and advanced disease, a Zubrodis performance status of 0 to 2, and measurable disease. No prior therapy was permitted. Twenty patients, 10 men and 10 women, having a mean age of 60 years enrolled in the study. Most patients (12 patients, 60%) had Stage IIIB disease and adenocarcinoma (13 patients, 65%). Four (20%) patients each had Stage IIIA and Stage IV disease and 7 (35%) patients had squamous cell tumors. Patients received a total of 62 cycles and an average of 3.1 cycles of gemcitabine therapy. Of the 18 patients included in the efficacy analyses, six were partial responders with a total response rate of 33.3%. Mean survival time was 7 months (2 to 15 months), mean progression-free survival time was 3.5 months (1 to 15 months), and the 1-year survival rate was 22.2%. World Health Organization (WHO) Grade 3 or 4 hematologic toxicities were observed in less than 2% of all cycles. The most common Grade 3 or 4 nonhematologic toxicities were nausea and vomiting observed in < 5% of cycles. Transient transaminase elevations were observed in < 4% of cycles. One patient presented with fulminant hepatitis and generalized vesicular rash believed by the investigators to be a hypersensibility reaction due to gemcitabine toxicity. In conclusion, singleagent gemcitabine administered as a weekly dose of 1000 mg/m 2 is safe and effective in the treatment of patients with advanced NSCLC." @default.
- W2181570036 created "2016-06-24" @default.
- W2181570036 creator A5002431859 @default.
- W2181570036 creator A5015219289 @default.
- W2181570036 creator A5021256397 @default.
- W2181570036 creator A5031289798 @default.
- W2181570036 creator A5058905478 @default.
- W2181570036 creator A5066901716 @default.
- W2181570036 date "2000-01-01" @default.
- W2181570036 modified "2023-10-14" @default.
- W2181570036 title "Gemcitabine in advanced non-small cell lung cancer: A phase II study" @default.
- W2181570036 cites W1579641819 @default.
- W2181570036 cites W1857358013 @default.
- W2181570036 cites W1858072261 @default.
- W2181570036 cites W2001996041 @default.
- W2181570036 cites W2168555194 @default.
- W2181570036 cites W2227314491 @default.
- W2181570036 hasPublicationYear "2000" @default.
- W2181570036 type Work @default.
- W2181570036 sameAs 2181570036 @default.
- W2181570036 citedByCount "0" @default.
- W2181570036 crossrefType "journal-article" @default.
- W2181570036 hasAuthorship W2181570036A5002431859 @default.
- W2181570036 hasAuthorship W2181570036A5015219289 @default.
- W2181570036 hasAuthorship W2181570036A5021256397 @default.
- W2181570036 hasAuthorship W2181570036A5031289798 @default.
- W2181570036 hasAuthorship W2181570036A5058905478 @default.
- W2181570036 hasAuthorship W2181570036A5066901716 @default.
- W2181570036 hasConcept C121608353 @default.
- W2181570036 hasConcept C126322002 @default.
- W2181570036 hasConcept C141071460 @default.
- W2181570036 hasConcept C143998085 @default.
- W2181570036 hasConcept C2776256026 @default.
- W2181570036 hasConcept C2776694085 @default.
- W2181570036 hasConcept C2776907518 @default.
- W2181570036 hasConcept C2778822529 @default.
- W2181570036 hasConcept C2780258809 @default.
- W2181570036 hasConcept C2780580376 @default.
- W2181570036 hasConcept C2780852908 @default.
- W2181570036 hasConcept C2781182431 @default.
- W2181570036 hasConcept C31760486 @default.
- W2181570036 hasConcept C71924100 @default.
- W2181570036 hasConcept C90924648 @default.
- W2181570036 hasConceptScore W2181570036C121608353 @default.
- W2181570036 hasConceptScore W2181570036C126322002 @default.
- W2181570036 hasConceptScore W2181570036C141071460 @default.
- W2181570036 hasConceptScore W2181570036C143998085 @default.
- W2181570036 hasConceptScore W2181570036C2776256026 @default.
- W2181570036 hasConceptScore W2181570036C2776694085 @default.
- W2181570036 hasConceptScore W2181570036C2776907518 @default.
- W2181570036 hasConceptScore W2181570036C2778822529 @default.
- W2181570036 hasConceptScore W2181570036C2780258809 @default.
- W2181570036 hasConceptScore W2181570036C2780580376 @default.
- W2181570036 hasConceptScore W2181570036C2780852908 @default.
- W2181570036 hasConceptScore W2181570036C2781182431 @default.
- W2181570036 hasConceptScore W2181570036C31760486 @default.
- W2181570036 hasConceptScore W2181570036C71924100 @default.
- W2181570036 hasConceptScore W2181570036C90924648 @default.
- W2181570036 hasIssue "3" @default.
- W2181570036 hasLocation W21815700361 @default.
- W2181570036 hasOpenAccess W2181570036 @default.
- W2181570036 hasPrimaryLocation W21815700361 @default.
- W2181570036 hasRelatedWork W1426247572 @default.
- W2181570036 hasRelatedWork W1871271676 @default.
- W2181570036 hasRelatedWork W2017544421 @default.
- W2181570036 hasRelatedWork W2022907323 @default.
- W2181570036 hasRelatedWork W2036953678 @default.
- W2181570036 hasRelatedWork W2040084516 @default.
- W2181570036 hasRelatedWork W2043119894 @default.
- W2181570036 hasRelatedWork W2047517255 @default.
- W2181570036 hasRelatedWork W2051504572 @default.
- W2181570036 hasRelatedWork W2053245757 @default.
- W2181570036 hasRelatedWork W2056584284 @default.
- W2181570036 hasRelatedWork W2064761286 @default.
- W2181570036 hasRelatedWork W2091323340 @default.
- W2181570036 hasRelatedWork W2093849386 @default.
- W2181570036 hasRelatedWork W2151189211 @default.
- W2181570036 hasRelatedWork W2171560504 @default.
- W2181570036 hasRelatedWork W2186247059 @default.
- W2181570036 hasRelatedWork W2416692481 @default.
- W2181570036 hasRelatedWork W2416780622 @default.
- W2181570036 hasRelatedWork W606431418 @default.
- W2181570036 hasVolume "46" @default.
- W2181570036 isParatext "false" @default.
- W2181570036 isRetracted "false" @default.
- W2181570036 magId "2181570036" @default.
- W2181570036 workType "article" @default.